Table 9.

The nature and severity of adverse events experienced by the dogs in the 2 treatment groups during the study. In the course of the study, dogs could experience more than 1 adverse event or experience more than 1 clinical sign at the time of an adverse event

	Pimobendan N = 179	Placebo N = 180	Total N = 359
Number of dogs experiencing at least 1 severe or worse adverse event	19 (10.6%)	19 (10.6%)	38 (10.6%)	P = .82
Number of dogs experiencing at least 1 mild or moderate adverse event (but not a severe or worse event)	61 (34.1%)	67 (37.2%)	128 (35.7%)
Number of dogs experiencing no adverse events	99 (55.3%)	94 (52.2%)	193 (53.8%)
Number of recorded adverse events
Severe or worse	23	21	44
Mild or moderate	145	153	298
Total	168	174	342
Frequency of specifically recorded adverse events
Diarrhea	21	14	35
Vomiting	27	27	54
Anorexia	7	12	19
Lethargy	13	15	28
Tachycardia	4	3	7
Other	124	147	271
Total	196	218	414